XNAS · Healthcare · Biotechnology
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the commercialization and development of neffy (currently identified in the European Union (EU) and United Kingdom (U.K.) by the trade name EURneffy and in China) for needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. Neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows Neffy to safely provide intranasal delivery of epinephrine at a low dose within the exposures of approved injectable products across a range of dosing conditions.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | Q1 2026 | -0.53 | -0.61 | -15.09% | $22.7M | ❌ Miss | +2.14% | +6.94% | — |
| 2026-03-09 | Q4 2025 | -0.46 | -0.42 | +8.70% | $28.1M | ✅ Beat | +0.33% | -3.87% | -9.50% |
| 2025-11-10 |
| Q3 2025 |
| -0.47 |
| -0.52 |
| -10.64% |
| $32.5M |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-13 | Q2 2025 | -0.47 | -0.46 | +2.13% | $15.7M | ✅ Beat | +3.48% | -7.71% | -36.60% |
| 2025-05-14 | Q1 2025 | -0.36 | -0.35 | +2.78% | $8.0M | ✅ Beat | — | — | — |
| 2025-03-20 | Q4 2024 | -0.12 | 0.48 | +500.00% | $86.6M | ✅ Beat | — | — | — |
| 2024-11-13 | Q3 2024 | -0.15 | -0.20 | -33.33% | $2.1M | ❌ Miss | — | — | — |
| 2024-08-06 | Q2 2024 | -0.12 | -0.13 | -8.33% | $500,000 | ❌ Miss | — | — | — |
Showing last 8 quarters.